A Longitudinal Cohort to Monitor Malaria Infection Incidence during Mass Drug Administration in Southern Province, Zambia

Rigorous evidence of effectiveness is needed to determine where and when to apply mass drug administration (MDA) or focal MDA (fMDA) as part of a malaria elimination strategy. The Zambia National Malaria Elimination Centre recently completed a community-randomized controlled trial in Southern Provin...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of tropical medicine and hygiene Vol. 103; no. 2_Suppl; pp. 54 - 65
Main Authors Bennett, Adam, Porter, Travis R, Mwenda, Mulenga C, Yukich, Joshua O, Finn, Timothy P, Lungu, Chris, Silumbe, Kafula, Mambwe, Brenda, Chishimba, Sandra, Mulube, Conceptor, Bridges, Daniel J, Hamainza, Busiku, Slutsker, Laurence, Steketee, Richard W, Miller, John M, Eisele, Thomas P
Format Journal Article
LanguageEnglish
Published United States The American Society of Tropical Medicine and Hygiene 01.08.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Rigorous evidence of effectiveness is needed to determine where and when to apply mass drug administration (MDA) or focal MDA (fMDA) as part of a malaria elimination strategy. The Zambia National Malaria Elimination Centre recently completed a community-randomized controlled trial in Southern Province to evaluate MDA and fMDA for transmission reduction. To assess the role of MDA and fMDA on infection incidence, we enrolled a longitudinal cohort for an 18-month period of data collection including monthly malaria parasite infection detection based on polymerase chain reaction and compared time to first infection and cumulative infection incidence outcomes across study arms using Cox proportional hazards and negative binomial models. A total of 2,026 individuals from 733 households were enrolled and completed sufficient follow-up for inclusion in analysis. Infection incidence declined dramatically across all study arms during the period of study, and MDA was associated with reduced risk of first infection (hazards ratio: 0.36; 95% CI: 0.16-0.80) and cumulative infection incidence during the first rainy season (first 5 months of follow-up) (incidence rate ratio: 0.34; 95% CI: 0.12-0.95). No significant effect was found for fMDA or for either arm over the full study period. Polymerase chain reaction infection status at baseline was strongly associated with follow-up infection. The short-term effects of MDA suggest it may be an impactful accelerator of transmission reduction in areas with high coverage of case management and vector control and should be considered as part of a malaria elimination strategy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
Authors’ addresses: Adam Bennett, Malaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, CA, E-mail: adam.bennett@ucsf.edu. Travis R. Porter, Joshua O. Yukich, Timothy P. Finn, and Thomas P. Eisele, Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, E-mails: tporter1@tulane.edu, jyukich@tulane.edu, tfinn2@tulane.edu, andteisele@tulane.edu. Mulenga C. Mwenda, Chris Lungu, Kafula Silumbe, Brenda Mambwe, Sandra Chishimba, Conceptor Mulube, Daniel J. Bridges, and John M. Miller, PATH Malaria Control and Elimination Partnership in Africa, Lusaka, Zambia, E-mails: mchimfwembe@path.org, clungu@path.org, ksilumbe@path.org, bmambwe@path.org, sandra.chishimba@gmail.com, cmulube@path.org, dbridges@path.org, and jmiller@path.org. Busiku Hamainza, National Malaria Elimination Center, Zambia Ministry of Health, Chainama Hospital Grounds, Lusaka, Zambia, E-mail: bossbusk@gmail.com. Laurence Slutsker, PATH Malaria Control and Elimination Partnership in Africa, Seattle, WA, E-mail: lslutsker@path.org. Richard W. Steketee, President’s Malaria Initiative, U.S. Agency for International Development, Washington, DC, E-mail: ris1@cdc.gov.
Financial support: This trial was an investigator-initiated study supported by a grant from the Bill & Melinda Gates Foundation.
ISSN:0002-9637
1476-1645
DOI:10.4269/ajtmh.19-0657